Description: Living Cell Technologies Limited (LCT) is an Australasian biotechnology company improving the wellbeing of people with serious diseases worldwide by discovering, developing and commercializing regenerative treatments which restore function using naturally occurring cells. LCT's lead product NTCELL is an alginate coated capsule containing clusters of neonatal porcine choroid plexus cells. After transplantation, NTCELL functions as a biological factory producing nerve growth factors to promote new central nervous system growth and repair disease induced nerve degeneration. The Phase I/IIa NTCELL clinical trial in New Zealand for the treatment of Parkinson's disease met the primary endpoint of safety and showed encouraging clinical efficacy improvements. Results from this trial will be used to design a larger Phase IIb trial to evaluate its potential as a disease-modifying treatment for patients with Parkinson's disease. It has the potential to be used in a number of other central nervous system indications such as Huntington's, Alzheimer's and motor neurone diseases. LCT's proprietary encapsulation technology, IMMUPEL, allows cell therapies to be used without the need for co-treatment with drugs that suppress the immune system. LCT holds a 50% interest in Diatranz Otsuka Limited which is developing a cell therapy for type 1 diabetes. LCT is listed on the Australian (ASX: LCT) and US (OTCQX: LVCLY) stock exchanges. The company is incorporated in Australia, with its operations based in New Zealand.
Home Page: www.lctglobal.com
Tower 2
Sydney,
NSW
2000
Australia
Phone:
61 3 8689 9997
Officers
| Name | Title |
|---|---|
| Dr. Bernard Tuch B.Sc., BSc, FRACP, GAICD, MBBS, MBBS (Hons), Ph.D. | Interim Chief Exec. Officer |
| Mr. Daya Uka | Chief Financial Officer |
| Dr. Belinda Di Bartolo | Chief Operations Officer |
| Mr. Mark Andrew Licciardo B Bus (Acc), FCIS, FGIA, GAICD, GradDip CSP | Company Sec. |
Exchange: OTCQB
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 3.5307 |
| Price-to-Sales TTM: | 3567.0686 |
| IPO Date: | |
| Fiscal Year End: | June |
| Full Time Employees: | 0 |